Some drugmakers are expanding production in Africa to take advantage of a growing number of countries where rising incomes and national healthcare can pay for new meds. Now, through a number of sources of financing, a new plant will be built to manufacture yellow fever vaccine, a protection that has been in short supply.
Johnson & Johnson has partnered with Cue to develop a portable, inexpensive and internet-enabled HIV viral load test that would enable physicians in poor countries to more easily determine if a particular drug regimen is effective or not.
Chinese biotech BeiGene is hoping to trade on the Nasdaq, filing for an IPO worth more than $150 million to support its pipeline of targeted cancer drugs.
Eye Tech Care has nabbed a commitment from China-focused investor Everpine Capital to invest about €24.8 million ($26.9 million) in two rounds. The firm has already invested an initial, undisclosed amount and it's working with the Lyon-based startup to gain a regulatory approval from the China Food and Drug Administration for its noninvasive glaucoma ultrasound treatment, which is already marketed in Europe.
Shanghai-headquartered drug developer Zai Lab said it locked up more than $100 million in Series B financing, raising cash from a syndicate including OrbiMed and Sequoia Capital.
Chinese drugmaker Simcere Pharmaceutical is plotting a Hong Kong IPO worth up to $1 billion, according to reports, joining a slew of local biopharma companies headed to the public markets.
In December 2015, the China FDA approved the first vaccine against the virus that causes hand, foot and mouth disease, a common infectious disease often found in children. But competition was not far behind: the agency approved a second vaccine against the virus on Monday, this one developed by Sinovac.
Jiangsu Hansoh Pharmaceutical, a Chinese drug developer, is moving toward a Hong Kong IPO worth up to $3 billion, according to Dow Jones.
After Q2's glacial emerging markets growth, industry watchers wondered just how slow pharma could go in developing countries. As it turns out, they found a way to decelerate in Q3.
Jin'ge (Chinese for "golden spear") from China's Guangzhou Baiyunshan is said to be on track to eclipse sales of Pfizer's Viagra in China in a few years with a price that is 60% less than the branded erectile dysfunction drug.